Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.
Finnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant.
The Budget Committee of the German Bundestag has announced to channel €38m in funding into the sustainable protein transition next year.
German precision fermentation specialist MicroHarvest GmbH has launched a single-cell protein pilot plant in Lison with an initial capacity of 25kg per day.
The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing.
Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.
The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already the largest European partnering event for biotech and pharma. However, many other figures are currently pointing back to 2019.
Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a €11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform.
German Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology.